Imugene is a publicly-listed biotechnology company with operations in America and Europe,
Imugene has raised $8.6M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Imugene's investors include Precision BioSciences.
Imugene is headquartered in Sydney, Australia.
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
Imugene is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Imugene — Funding & Investors." VCBacked, April 23, 2026, https://www.vcbacked.co/company/imugene. Accessed August 14, 2026.
VCBacked. (2026). Imugene — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/imugene
{{cite web |title=Imugene — Funding & Investors |url=https://www.vcbacked.co/company/imugene |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated